The Cell and Molecular Imaging (CMI) platform makes the visualization of biological systems, from the molecular to the tissue level possible. Cryo-EM enables the reconstruction of near-atomic structures of molecular

Medow has successfully landed its largest sales agreement to date – which is also the largest business deal that a SmiLe company has made during its time in the incubator

Atos Medical has announced the acquisition of the German tracheostomy company TRACOE medical, including NL-based MC Europe and of UK-based Kapitex Healthcare. “I am truly excited that TRACOE, MC Europe

Nanoform has announced that Proof of Concept studies will be funded by the Bill & Melinda Gates Foundation. The funding will be used to assess the added value Nanoform’s CESS

The company has received a prestigious Guldpillret (Golden Pill) award for its home blood sampling device. Established by Läkemedelsförsäkringen, the prize is awarded annually to highlight the need for better

SmartCella Holding has announced the raising to further advance and accelerate the development of core technologies in the company’s three business units, Procella Therapeutics, Smartwise and SvedMed Solutions. The financing,

Oslo Innovation Week, on behalf of the City of Oslo and Innovation Norway, has announced that the medical technology startup, EpiGuard is the recipient of the 2021 Oslo Innovation Award.

Aegirbio acquires the health tech company Dynamic Code, and states that it is now embarking on the strategic construction of an international operator in the rapidly evolving domain of e-health.

Elekta has acquired its long-time partner and Turkish distributor of neurosurgery solutions, Özyürek Mümessillik ve Dış Ticaret A.Ş. The acquisition will improve Elekta’s market access in the region and strengthen

BICO has acquired all outstanding shares in Advanced BioMatrix, an American company focusing on 3D research applications. The Advanced BioMatrix portfolio includes collagen bioinks, high purity extracellular matrix proteins, chemically

Photocure has reached agreement with BioSyent Pharma to reacquire the marketing and distribution rights to Cysview in Canada. The parties entered into a final agreement, stipulating that commercial rights will

CELLINK Life Sciences has changed name to BICO (BIo COnvergence) while maintaining the CELLINK name for the bioprinting business. The Group has transformed itself to create a more growth-oriented business

Immunovia, Inc has received final approval to begin patient testing for the IMMray PanCan-d test. The IMMray PanCan-d test is the first blood test on the market dedicated to the

The company has received CE mark approval for a neuromodulation treatment of Chronic Migraine. The Swedish company’s existing EC-certificate for K.O.S has now been granted an extension with the indication

The company has entered into an agreement with the shareholders of Discover Echo to acquire all outstanding shares to a purchase price of USD 110 million. Approximately eleven percent of

The Issue was subscribed for by several new Swedish and international institutional investors, such as Alcur Fonder, FE Fonder and Humle Fonder, as well as several existing owners, such as

The Norwegian scientist wins the Industry category, sector Medical device, for his invention of better nasal drug delivery. Djupesland’s device for administering medicine via the nose brings relief to millions

The company has Sold its First NEOLA System to Tyndall National Institute at University College Cork to be used for a large study on newborn infants within the Irish Centre

Swedish radiopharmaceutical production company Alpha Therapy Solutions and Advanced Nuclear Medicine Ingredients S.A., a wholly owned European subsidiary of Telix Pharmaceuticals Limited, have been jointly awarded a 990,000 EUR, a

Nanoform and Celanese Corporation have announced plans to explore the synergies between their respective technologies in the field of nanoparticle-enabled drug delivery. The goal is to assess the utility of

Today, on 26 May 2021, the Medical Device Regulation (MDR) will become fully applicable, following the transition period. What does this mean and what do medical device companies and others